A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

~10 mi. (Riverhead, New York, +127 more cities)

North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists

BRAF V600E

Colorectal Carcinoma

cetuximab, +3 more drugs

chemotherapy, +1 more type

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

~24 mi. (Port Jefferson Station, New York, +266 more cities)

Research Site

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +2 more drugs

targeted therapy

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

~24 mi. (Port Jefferson Station, New York, +271 more cities)

New York Cancer and Blood Specialists

Prostate Adenocarcinoma

docetaxel, +2 more drugs

chemotherapy, +2 more types

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~24 mi. (Port Jefferson Station, New York, +206 more cities)

New York Cancer & Blood Specialists

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

AVB-S6-500 (Batiraxcept)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

~24 mi. (Port Jefferson Station, New York, +56 more cities)

North Shore Hematology Oncology Assoc. DBA NY Cancer and Blood Specialists

High Grade Fallopian Tube Serous Adenocarcinoma, +2 more conditions

batiraxcept, +1 more drug

chemotherapy, +1 more type

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

~24 mi. (Port Jefferson Station, New York, +115 more cities)

New York Cancer and Blood Specialists-Research Department ( Site 0080)

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

~24 mi. (Port Jefferson Station, New York, +61 more cities)

Research Site

KRAS G12C

Colorectal Carcinoma

adagrasib, +1 more drug

targeted therapy

Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

~24 mi. (Port Jefferson Station, New York, +60 more cities)

North Shore Hematology Oncology Associates P.C. DBA NY Cancer and Blood Specialists

EGFR A763_Y764insFQEA, +31 more biomarkers

Non-Small Cell Lung Carcinoma

poziotinib

targeted therapy

Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

~24 mi. (Port Jefferson Station, New York, +13 more cities)

Ny Cancer And Blood Specialists

Non-Small Cell Lung Carcinoma

chemotherapy, +2 more drugs

chemotherapy, +1 more type

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

~24 mi. (Port Jefferson Station, New York, +47 more cities)

New York Cancer & Blood Specialists

AKT1 Mutation, +17 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +11 more drugs

chemotherapy, +2 more types

A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies

~24 mi. (Port Jefferson Station, New York, +1 more cities)

North Shore Hematology Oncology Associates. DBA New York Cancer and Blood Specialists

Complex karyotype, +2 more biomarkers

Acute Myeloid Leukemia, +3 more conditions

PRT1419

targeted therapy

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

~24 mi. (Port Jefferson Station, New York, +63 more cities)

New York Cancer and Blood Specialists

FGFR1 Fusion, +5 more biomarkers

Malignant Solid Tumor, +1 more condition

atezolizumab, +1 more drug

immunotherapy, +1 more type